Qian-Qian Shen
Overview
Explore the profile of Qian-Qian Shen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
65
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jia H, Chen J, Zhai Z, Fan W, Yuan S, Liu Q, et al.
Eur Thyroid J
. 2023 Nov;
12(6).
PMID: 37992281
Introduction: Thyroid metastasis from clear cell renal cell carcinoma (ccRCC) is relatively rare, so ultrasound doctors lack experience with the disease, which can easily lead to misdiagnosis. We describe three...
2.
Yu L, Wang Y, Xiao J, Shen Q, Chi S, Gao Y, et al.
Acta Pharmacol Sin
. 2023 May;
44(10):2113-2124.
PMID: 37225847
EZH2 has been regarded as an efficient target for diffuse large B-cell lymphoma (DLBCL), but the clinical benefits of EZH2 inhibitors (EZH2i) are limited. To date, only EPZ-6438 has been...
3.
Zhang C, Jin R, Shen Q, Liu L
Environ Sci Pollut Res Int
. 2022 Nov;
30(11):29844-29858.
PMID: 36418827
Heavy metal ion (HMI) in wastewater is a kind of resource that is wrongly placed. Recovery of heavy metal from lead-acid wastewater desires efficient and reusable functional materials. In this...
4.
Zhang K, Shen Q, Fang Y, Sun Y, Ding J, Chen Y
Acta Pharmacol Sin
. 2020 Feb;
41(5):733-734.
PMID: 32060412
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
5.
Zhang S, Gong C, Su M, Chen F, He T, Zhang Y, et al.
J Med Chem
. 2019 Dec;
63(2):804-815.
PMID: 31855601
A series of bisthiazole-based hydroxamic acids as novel potent HDAC inhibitors was developed during our previous work. In the present work, a new series of highly potent bisthiazole-based compounds were...
6.
He P, Shen Q, Chen Y, Yu J, Li Z, Ouyang X
Nurs Health Sci
. 2019 Nov;
22(2):364-373.
PMID: 31698541
Patient empowerment has been shown to have some positive impacts on self-efficacy, self-esteem, and recovery. However, information about the empowerment needs of patients after a percutaneous coronary intervention is scarce....
7.
Zhang K, Shen Q, Fang Y, Sun Y, Ding J, Chen Y
Acta Pharmacol Sin
. 2019 Jun;
40(12):1587-1595.
PMID: 31171828
Deregulated Polycomb repressive complex 2 (PRC2) is intimately involved in tumorigenesis and progression, making it an invaluable target for epigenetic cancer therapy. Disrupting the EZH2-EED interaction, which is required for...
8.
He P, Shen Q, Wen M, Zou J, Wang Y, Yang J, et al.
Biochem Biophys Res Commun
. 2018 Nov;
508(1):97-101.
PMID: 30471854
Nobiletin has protective effects on cardiovascular diseases, but the mechanism is not clear. In this study, we examined whether nobiletin affects the expression of miR-590/LPL and its relative effects on...
9.
He P, Jiang T, Ouyang X, Liang Y, Zou J, Wang Y, et al.
Clin Chim Acta
. 2018 Feb;
480:126-137.
PMID: 29453968
Lipoprotein lipase (LPL) is a rate-limiting enzyme that catalyzes hydrolysis of the triglyceride (TG) core of circulating TG-rich lipoproteins including chylomicrons (CM), low-density lipoproteins (LDL) and very low-density lipoproteins (VLDL)....